Levorphanol versus methadone use: safety considerations.
Levorphanol
N-methyl-D-aspartate receptors (NMDA receptors)
methadone
opioids
safety
Journal
Annals of palliative medicine
ISSN: 2224-5839
Titre abrégé: Ann Palliat Med
Pays: China
ID NLM: 101585484
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
01
01
2020
accepted:
24
01
2020
pubmed:
12
3
2020
medline:
14
4
2020
entrez:
12
3
2020
Statut:
ppublish
Résumé
Methadone has unique characteristics that make it an attractive agent for the treatment of chronic pain and opioid drug dependence. However, methadone prescription requires more clinical experience and close monitoring of patients to avoid its undesirable side effects. Recently, levorphanol has emerged as "a forgotten opioid" with a similar profile as methadone. Levorphanol has no impact on QTc prolongation and considerably less drug-drug interactions as compared to methadone. Lack of commercial availability, providers' unfamiliarity, and limited clinical data on its effectiveness remain practical issues. The objective of this article is to review and compare the safety considerations for methadone and levorphanol use.
Identifiants
pubmed: 32156130
pii: apm.2020.02.01
doi: 10.21037/apm.2020.02.01
doi:
Substances chimiques
Analgesics, Opioid
0
Levorphanol
27618J1N2X
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM